Interview with Hervé Dussart , President, AstraZeneca Turkey
Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man…
Address: Büyükdere Cad. Yapı Kredi Plaza, B Blok, K:2-4, 34330 Levent – Istanbul / Turkey
,Turkey
Tel: +90 212 317 2300
Web: http://www.astrazeneca.com.tr/
Since 1999 with the mission to produce ideas that add value for the life of people spend their lives working for better quality, and performs a lot of research, AstraZeneca, has been undertaking major projects in Turkey within the framework of social responsibility . AstraZeneca to gain awareness of first aid at a young age, ‘First Aid’ project TOÇEV throughout Turkey and in conjunction with the Ministry of National Education conducts. Investigating the effects of socioeconomic and environmental factors on human health and will continue for 10 years, ‘Prospective Urban and Rural Epidemiology’ ‘PURE’ gold sponsor of the research all over the world. Continued under the leadership of our country, METSEND’in approximately 3000 people were included in this project. not only the disease-causing diseases, and investigating the causes and environments that support the work of public awareness in order to eliminate these causes, AstraZeneca, ‘Fast Forward-fast-forward’ approach, using the maximum to produce beneficial drugs, the patient needs to provide the most appropriate solutions and business processes through the developing world to adapt the driving force attack is considered.
AstraZeneca, research, development, prescription drugs, production, marketing and presentation of these services in the field, one of the most important international companies. Volume of $ 33 billion health care and chest infection, cardiology, gastroentereloji, oncology, central nervous system and leading position in diabetes care products offered by area is one of the world’s leading pharmaceutical companies
Even though you have delivered strong results in most of the markets you have been appointed, this is your first assignment as the head of a subsidiary. For a man…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
See our Cookie Privacy Policy Here